Работы, цитирующие эту работу

Работ: 3

Работа: Long-term outcomes following CAR T cell therapy: what we know so far

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   СтатьяCAR-T cell therapy researchJournal of Hematology & Oncology2025Цитирований: 0

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

   Qianqian Huang, Fan Tong, Jiantao Chen +5

   Обзорная статьяNanoplatforms for cancer theranosticsAdvanced Science2025Цитирований: 0

   ABIABI:AkademIndex/openalex/2025.review-article.000021

3. Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   СтатьяCancer Immunotherapy and BiomarkersAnnals of Hematology2026Цитирований: 0

   ABIABI:AkademIndex/openalex/2026.article.009488